Portage Biotech (NASDAQ: PRTG) is one of 268 publicly-traded companies in the “Crude petroleum & natural gas” industry, but how does it compare to its rivals? We will compare Portage Biotech to similar businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, risk and dividends.
Earnings & Valuation
This table compares Portage Biotech and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Portage Biotech||N/A||-$15.83 million||-14.62|
|Portage Biotech Competitors||$5.49 billion||-$638.49 million||-3.59|
This is a summary of current ratings and price targets for Portage Biotech and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Portage Biotech Competitors||2102||10497||15048||514||2.50|
Portage Biotech presently has a consensus target price of $35.00, indicating a potential upside of 77.30%. As a group, “Crude petroleum & natural gas” companies have a potential upside of 20.18%. Given Portage Biotech’s stronger consensus rating and higher probable upside, research analysts plainly believe Portage Biotech is more favorable than its rivals.
Insider and Institutional Ownership
7.1% of Portage Biotech shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Crude petroleum & natural gas” companies are owned by institutional investors. 11.0% of shares of all “Crude petroleum & natural gas” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Portage Biotech and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Portage Biotech Competitors||-32.98%||-38.93%||4.07%|
Portage Biotech Company Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.